http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8#Head
http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8#assertion
http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8#provenance
http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8#pubinfo
http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8#assertion
http://purl.obolibrary.org/obo/DOID_13146
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_13146
http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00520
http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8#association
http://www.w3.org/2000/01/rdf-schema#label
caspofungin acetate is an echinocandin antifungal indicated in adults and pediatric patients 3 months of age and older for empirical therapy for presumed fungal infections in febrile neutropenic patients 1 treatment of candidemia and the following candida 1 treatment of esophageal candidiasis 1 treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies 1 caspofungin acetate for injection is indicated as empirical therapy for presumed fungal infections in febrile neutropenic adult and pediatric patients 3 months of age and older see clinical studies 14 1 14 5 caspofungin acetate for injection is indicated for the treatment of candidemia and the following candida infections intra abdominal abscesses peritonitis and pleural space infections in adult and pediatric patients 3 months of age and older see clinical studies 14 2 14 5 limitations of use candida caspofungin acetate for injection is indicated for the treatment of esophageal candidiasis in adult and pediatric patients 3 months of age and older see clinical studies 14 3 14 5 limitations of use see clinical studies 14 3 caspofungin acetate for injection is indicated for the treatment of invasive aspergillosis in adult and pediatric patients 3 months of age and older who are refractory to or intolerant of other therapies see clinical studies 14 4 14 5 limitations of use
http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB00520
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8#provenance
http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8#pubinfo
http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8#sig
http://purl.org/nanopub/x/hasSignature
WJSKHDkHvF5pI97AfODVSSuuoGGHmcj2X/YcTrOd6TLd7UWKy9WpFxSyV64oEh/6mYGoGyos22dI16+E5ATJIqxAUlNfc+EtY6HCtf3Nr3/zwojqrF/mrMtaCKRVfQqLemynRYmGvwc93KMezAM/ezGRE5aAV8wLUImYA6MjGVE=
http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8
http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8
http://purl.org/dc/terms/created
2021-06-13T16:37:05.692+02:00
http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs